Jiangsu Hengrui PharmaceuticalsLtd (0BO) Stock Overview
A pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0BO from our risk checks.
0BO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.85 |
| 52 Week High | CN¥10.40 |
| 52 Week Low | CN¥5.72 |
| Beta | 0.42 |
| 1 Month Change | -12.78% |
| 3 Month Change | -8.19% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 22.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0BO | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.9% | 0.9% | 0.5% |
| 1Y | n/a | -11.4% | 14.2% |
Return vs Industry: Insufficient data to determine how 0BO performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0BO performed against the German Market.
Price Volatility
| 0BO volatility | |
|---|---|
| 0BO Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0BO has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 0BO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | 20,238 | Ji Feng | www.hengrui.com |
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Fundamentals Summary
| 0BO fundamental statistics | |
|---|---|
| Market cap | €50.02b |
| Earnings (TTM) | €905.88m |
| Revenue (TTM) | €3.76b |
Is 0BO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0BO income statement (TTM) | |
|---|---|
| Revenue | CN¥30.98b |
| Cost of Revenue | CN¥4.24b |
| Gross Profit | CN¥26.74b |
| Other Expenses | CN¥19.27b |
| Earnings | CN¥7.47b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.13 |
| Gross Margin | 86.31% |
| Net Profit Margin | 24.10% |
| Debt/Equity Ratio | 0% |
How did 0BO perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/12 23:51 |
| End of Day Share Price | 2025/11/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jiangsu Hengrui Pharmaceuticals Co.,Ltd is covered by 46 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Yanan Hou | Bohai Securities Co., Ltd. |
| Shun Kei Law | CCB International Securities Limited |